☰

Beatrice Gini, Ph.D. - Publications

Affiliations: 
Molecular Pathology Ludwig Institute for Cancer Research, San Diego, CA, United States 
Website:
http://www.ludwigsd.org/labs/molecular_pathology/people/
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Caswell DR, Gui P, Mayekar MK, Law EK, Pich O, Bailey C, Boumelha J, Kerr DL, Blakely CM, Manabe T, Martinez-Ruiz C, Bakker B, De Dios Palomino Villcas J, I Vokes N, Dietzen M, ... ... Gini B, et al. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. Nature Genetics. PMID 38049664 DOI: 10.1038/s41588-023-01592-8  0.383
2020 Gini B, Thomas N, Blakely CM. Impact of concurrent genomic alterations in epidermal growth factor receptor ()-mutated lung cancer. Journal of Thoracic Disease. 12: 2883-2895. PMID 32642201 DOI: 10.21037/Jtd.2020.03.78  0.496
2017 Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics. PMID 29106415 DOI: 10.1038/Ng.3990  0.459
2017 Gu Y, Albuquerque CP, Braas D, Zhang W, Villa GR, Bi J, Ikegami S, Masui K, Gini B, Yang H, Gahman TC, Shiau AK, Cloughesy TF, Christofk HR, Zhou H, et al. mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. Molecular Cell. PMID 28648777 DOI: 10.1016/J.Molcel.2017.05.030  0.679
2016 Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, et al. Inactivation of Capicua drives cancer metastasis. Nature Genetics. PMID 27869830 DOI: 10.1038/Ng.3728  0.359
2016 Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, ... ... Gini B, et al. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 29: 563-73. PMID 27070703 DOI: 10.1016/J.Ccell.2016.03.012  0.738
2015 Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, Masui K, Gini B, Yang H, Hosoda K, Sasaki R, et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. The Journal of Clinical Investigation. 125: 1591-602. PMID 25798620 DOI: 10.1172/Jci78239  0.744
2015 Shin YS, Wei W, Gini B, Mischel P, Heath J. Abstract PR09: Single cell phosphoproteomics identifies adaptive network dynamics of mTOR inhibitor resistance and defines effective combination therapy in glioblastoma Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Pr09  0.653
2014 Gini B, Mischel PS. Greater than the sum of its parts: single-nucleus sequencing identifies convergent evolution of independent EGFR mutants in GBM. Cancer Discovery. 4: 876-8. PMID 25092745 DOI: 10.1158/2159-8290.Cd-14-0635  0.578
2014 Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (New York, N.Y.). 343: 72-6. PMID 24310612 DOI: 10.1126/Science.1241328  0.704
2014 Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Masui K, Gini B, Yang H, Mischel PS, Kohmura E. NT-39 * GLUTAMINASE-MEDIATED METABOLIC PATHWAY INVOLVES GLIOBLASTOMA RESISTANCE TO mTOR-TARGETED THERAPIES Neuro-Oncology. 16: v167-v167. DOI: 10.1093/Neuonc/Nou265.37  0.699
2014 Gini B, Bonetti B, Mischel P. Hypoxia Regulation of Sensitivity to the Mechanistic Target of Rapamycin Kinase Inhibition (Mtorki) in Glioblastoma Multiforme Annals of Oncology. 25: iv571. DOI: 10.1093/Annonc/Mdu359.28  0.623
2013 Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metabolism. 18: 726-39. PMID 24140020 DOI: 10.1016/J.Cmet.2013.09.013  0.691
2013 Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5722-32. PMID 24030701 DOI: 10.1158/1078-0432.Ccr-13-0527  0.742
2013 Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metabolism. 17: 1000-8. PMID 23707073 DOI: 10.1016/J.Cmet.2013.04.013  0.673
2013 Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee WK. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis. 34: 725-38. PMID 23455378 DOI: 10.1093/Carcin/Bgt086  0.667
2013 Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee WK, Cloughesy TF, Furnari FB, Nakamura M, et al. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 4339-44. PMID 23440206 DOI: 10.1073/Pnas.1217602110  0.744
2012 Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper RO, Mischel PS, James CD, Berger MS, Ronen SM. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. Neuro-Oncology. 14: 1050-61. PMID 22670012 DOI: 10.1093/Neuonc/Nos126  0.538
2012 Babic I, Gini B, Tanaka K, Jacobs C, Yong WH, Cloughesy TF, Mischel PS. Abstract 4321: EGFR signaling in glioblastoma regulates the expression of a brain specific isoform ofalphaPIX/Arhgef6to promote invasion Cancer Research. 72: 4321-4321. DOI: 10.1158/1538-7445.Am2012-4321  0.419
2012 Gini B, Guo D, Nathanson D, Shackelford D, Zhu S, Yang H, Tanaka K, Babic I, Akhavan D, Bonetti B, Mortensen D, Xu S, Raymon H, Chopra R, Mischel P. Abstract 1923: The mTOR kinase inhibitor, CC214, preferentially blocks the growth of EGFRvIII-activated glioblastomas Cancer Research. 72: 1923-1923. DOI: 10.1158/1538-7445.Am2012-1923  0.671
2011 Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discovery. 1: 524-38. PMID 22145100 DOI: 10.1158/2159-8290.Cd-11-0124  0.665
2011 Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discovery. 1: 442-56. PMID 22059152 DOI: 10.1158/2159-8290.Cd-11-0102  0.656
Show low-probability matches.